HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rexall Showcase Challenging Florida AG Over Trade Secret Disclosure

This article was originally published in The Tan Sheet

Executive Summary

Rexall Sundown's direct sales division, Rexall Showcase International, has filed suit against the state of Florida to protect the confidentiality of trade secrets it believes will be made public during a probe of the company's business practices.

You may also be interested in...



Quigley "Eezes" In Direct Sales Subsidiary, New Products

A new Web-based direct sales subsidiary will help Quigley experience "bottom line benefits" next year, the Cold-Eeze marketer announced June 21.

Rexall Showcase International

Rexall's direct sales subsidiary voluntarily dismisses its complaint against the Florida Attorney General's office May 22. RSI filed a lawsuit hoping to prevent the AG from forcing the company to turn over a variety of documents related to an ongoing pyramid scheme investigation (1"The Tan Sheet" April 3, p. 10). Rexall had argued the information was protected by trade secret laws, but canceled the scheduled hearing and will turn over all relevant papers. The AG says the company reserves the right to object to any future request for documents

Numico Rexall Showcase Intl. Purchase Heightens Direct Sales Presence

Netherlands-based Royal Numico has significantly strengthened its multilevel marketing operations with the addition of Rexall Showcase International. Numico is acquiring RSI parent Rexall Sundown, in a $1.8 bil. deal expected to close by early July.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel